Intrexon | XON - Loan Capital


Intrexon reported $0 in Loan Capital for its fiscal quarter ending in June of 2024.





Loan Capital Change Date
Agenus USD 153.98M 15.68M Mar/2026
Alaunos Therapeutics USD 4.47M 5.85M Jun/2022
Amgen USD 51.86B 27M Jun/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Heron Therapeutics USD 140.64M 975K Dec/2025
Incyte USD 28.42M 994K Jun/2026
Intrexon USD 0 198.67M Jun/2024
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Ligand Pharmaceuticals USD 446.9M 704K Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
MannKind USD 545.13M 2.93M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Novartis USD 37.49B 42M Jun/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Roche Holding CHF 25.22B 2.21B Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Thermo Fisher Scientific USD 39.18B 890M Jun/2026
Veracyte USD 0 0 Mar/2025
Xencor USD 77.54M 4.59M Jun/2026